{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:38:29Z","timestamp":1784133509209,"version":"3.55.0"},"reference-count":32,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,16]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Alopecia areata (AA) is a chronic immune-related disease with non-scarring hair loss. Treatment may reduce disease activity but cannot cure. Even though AA can be very burdensome to patients, the German social act has categorised AA as a \u2018lifestyle disease\u2019 and treatment is not covered by statutory health insurances (SHI). We aimed to characterise the healthcare situation of patients with AA in Germany, including potential inequalities, and to derive recommendations for action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This mixed-methods study combined: (1) semistructured qualitative interviews with patients and dermatologists, analysed through qualitative content analysis and (2) claims data analyses of a large nationwide German SHI from 2016 to 2020. Both types of data were collected and analysed in parallel to enable integrated analysis. Consecutively, an expert panel derived recommendations for action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Interviews were conducted online or via telephone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients were recruited conveniently via a dermatological outpatient clinic, patient organisations and social media. Dermatologists were recruited from a nationwide network and the dermatological societies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Exploration of the healthcare situation of adult persons with AA in Germany, investigating potential barriers to adequate care and identifying potential inequalities of access to care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We interviewed 20 patients (mean age 40.7 years; 75.0% female) and 14 dermatologists (mean age 48.4 years, 50.0% female). SHI data included 4692 persons with AA in 2020 (prevalence 0.23%; mean age 55.8 years; 76.2% female). The lack of reimbursement was criticised by both patients and dermatologists. Though 57.5% of patients received at least one drug prescription, mostly topical therapies, access to approved systemic drugs was very low. Drugs were prescribed mostly by general practitioners (41.1%) and dermatologists (32.8%). Some patients were sceptical regarding the side effects of treatment and criticised exclusively symptomatic treatment. Patients reported an urge for information and exchange with others, as well as different ways of handling their disease, such as acceptance, and frustration or desperation. Patients living in urban areas received topical therapies more often than patients in rural areas. Furthermore, women were more likely to receive treatment than men. Recommendations for action include reimbursement of AA medication and developing a platform providing information on AA to physicians and patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The disease burden and frustration of patients with AA is high, mostly caused by limited treatment options and lack of reimbursement, limiting access to approved drugs such as Janus kinase inhibitors.<\/jats:p>\n                    <jats:p>Through the mixed-methods design, we were able to combine patient experiences and quantitative data reflecting the reality of healthcare in Germany.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-098802","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:40:51Z","timestamp":1748587251000},"page":"e098802","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Identifying barriers and disparities in the healthcare of patients with alopecia areata: a mixed-methods analysis using claims data and qualitative interview data"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9861-9519","authenticated-orcid":false,"given":"Toni Maria","family":"Janke","sequence":"first","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beke","family":"Hester","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-1639","authenticated-orcid":false,"given":"Christine","family":"Blome","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Klinger","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Stephan","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2676-1479","authenticated-orcid":false,"given":"Kristina","family":"Hagenstr\u00f6m","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2025121600173921000_15.5.e098802.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1142"},{"key":"2025121600173921000_15.5.e098802.2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2147\/CCID.S376096","article-title":"Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs","volume":"16","author":"Alhanshali","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025121600173921000_15.5.e098802.3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","article-title":"Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review","volume":"11","author":"Mostaghimi","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025121600173921000_15.5.e098802.4","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s13555-023-01057-0","article-title":"Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries","volume":"13","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025121600173921000_15.5.e098802.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1141"},{"key":"2025121600173921000_15.5.e098802.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.10.031"},{"key":"2025121600173921000_15.5.e098802.7","unstructured":"Deutsche Dermatologische Gesellschaft e.V. S3-Leitlinie Diagnostik und Therapie der Alopecia areata: Neuanmeldung, Registernummer 013-104. Available: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-104#anmeldung [Accessed 10 Jul 2023]."},{"key":"2025121600173921000_15.5.e098802.8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025121600173921000_15.5.e098802.9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/bjd\/ljad381","article-title":"Epidemiology of alopecia areata and population-wide comorbidities in Germany: analysis of longitudinal claims data","volume":"190","author":"Augustin","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025121600173921000_15.5.e098802.10","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1007\/s12325-021-01845-0","article-title":"Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims","volume":"38","author":"Senna","year":"2021","journal-title":"Adv Ther"},{"key":"2025121600173921000_15.5.e098802.11","first-page":"1012","article-title":"Treatment of Alopecia Areata in the United States: A Retrospective Cross-Sectional Study","volume":"14","author":"Farhangian","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"2025121600173921000_15.5.e098802.12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bjd.20628","article-title":"The epidemiology of alopecia areata: a population-based cohort study in UK primary care","volume":"186","author":"Harries","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025121600173921000_15.5.e098802.13","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.4441","article-title":"Out-of-Pocket Costs in Alopecia Areata: A Cross-Sectional Study in German-speaking Countries","volume":"103","author":"Kullab","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2025121600173921000_15.5.e098802.14","unstructured":"Gemeinsamer Bundesausschuss . Tragende Gr\u00fcnde zum Beschlussentwurf des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL) Anlage II \u2013 Lifestyle Arzneimittel Erg\u00e4nzung und Aktualisierung. Available: https:\/\/www.g-ba.de\/downloads\/40-268-5354\/2018-10-18_AM-RL-II-Ergaenzung-Aktualisierung_TrG.pdf [Accessed 26 Jul 2024]."},{"key":"2025121600173921000_15.5.e098802.15","unstructured":"Federal Ministry of Health . Statuatory health insurance (SHI). 2024. Available: https:\/\/www.bundesgesundheitsministerium.de\/\/gkv [Accessed 18 Dec 2024]."},{"key":"2025121600173921000_15.5.e098802.16","doi-asserted-by":"crossref","unstructured":"King N , Horrocks C , Brooks J . Interviews in qualitative research. 2nd edn. SAGE, 2019.","DOI":"10.4135\/9781036234881"},{"key":"2025121600173921000_15.5.e098802.17","unstructured":"Kuckartz U . Qualitative Inhaltsanalyse: Methoden, Praxis, Computerunterst\u00fctzung. 4th edn. Beltz Juventa, 2018."},{"key":"2025121600173921000_15.5.e098802.18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.zefq.2014.08.022","article-title":"[STandardized Reporting Of Secondary data Analyses (STROSA)\u2014a recommendation]","volume":"108","author":"Swart","year":"2014","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"2025121600173921000_15.5.e098802.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00500-x"},{"key":"2025121600173921000_15.5.e098802.20","unstructured":"KBV. National Association of Statuatory Health Insurance Physicians [Kassen\u00e4rztliche Bundesvereinigung] . Key tables [Schl\u00fcsseltabellen].: Richtlinie der Kassen\u00e4rztlichen Bundesvereinigung nach \u00a7 75 Absatz 7 SGB V zur Vergabe der Arzt-, Betriebsst\u00e4tten-, Praxisnetz- sowie der Netzverbundnummern. 2024. Available: https:\/\/www.kbv.de\/media\/sp\/Arztnummern_Richtlinie.pdf"},{"key":"2025121600173921000_15.5.e098802.21","unstructured":"U.S. Food and Drug Administration . FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). Available: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and [Accessed 23 Apr 2025]."},{"key":"2025121600173921000_15.5.e098802.22","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte . Rote-Hand-Brief zu Januskinase-Inhibitoren: Aktualisierte Empfehlungen zur Minimierung der Risiken. Available: https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2023\/rhb-januskinase.html [Accessed 23 Apr 2025]."},{"key":"2025121600173921000_15.5.e098802.23","unstructured":"U.S. Food and Drug Administration . FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Available: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death [Accessed 23 Apr 2025]."},{"key":"2025121600173921000_15.5.e098802.24","unstructured":"Drugs.com . FDA arthritis advisory committee recommends approval of tofacitinib for adult patients with moderately to severely active rheumatoid arthritis. Available: https:\/\/www.drugs.com\/nda\/tofacitinib_120509.html [Accessed 23 Apr 2025]."},{"key":"2025121600173921000_15.5.e098802.25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40261-023-01260-z","article-title":"Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review","volume":"43","author":"Papierzewska","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2025121600173921000_15.5.e098802.26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/CLEP.S315888","article-title":"Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis","volume":"13","author":"Hagenstr\u00f6m","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2025121600173921000_15.5.e098802.27","first-page":"59","article-title":"Alopecia areata - Current understanding and management","volume":"20","author":"Lintzeri","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025121600173921000_15.5.e098802.28","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","article-title":"Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study","volume":"20","author":"Mesinkovska","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2025121600173921000_15.5.e098802.29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjd.19598","article-title":"A qualitative exploration of the experiences of adolescents with alopecia areata and their messages for healthcare professionals","volume":"184","author":"de Vere Hunt","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025121600173921000_15.5.e098802.30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12030964","article-title":"Systematic Review of Psychological Interventions for Quality of Life, Mental Health, and Hair Growth in Alopecia Areata and Scarring Alopecia","volume":"12","author":"Maloh","year":"2023","journal-title":"J Clin Med"},{"key":"2025121600173921000_15.5.e098802.31","doi-asserted-by":"crossref","unstructured":"Swart E . Health care utilization research using secondary data. In: Health care utilization in Germany. New York: Springer, 2014: 63\u201386.","DOI":"10.1007\/978-1-4614-9191-0_5"},{"key":"2025121600173921000_15.5.e098802.32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1275711"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-098802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:17:53Z","timestamp":1765873073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-098802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2025-098802"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-098802","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}